SYNGENE

It was incorporated as Syngene International Private Limited as on November 18, 1993, at Bengaluru, Karnataka as a private limited company under the Companies Act, 1956. According to a special resolution of the shareholders dated March 26, 2007, the Company was being converted into a public limited company, and the company name was changed to Syngene International Limited. Also, a fresh certificate of incorporation consequent upon conversion to the public limited company was issued as on April 19, 2007. It was also promoted by Kiran Mazumdar Shaw, who is a promoter of Biocon. On March 30, 2002, 99.9% of the Equity Shares of the Company were being transferred to Biocon, and as a result, it became the subsidiary of Biocon. It has also since been the Promoter of the Company. Also, the details of changes in the registered office of the Company are given below: From 20th KM, Hosur Road, Electronics City P.O, Bengaluru 560 100, Karnataka, India to Biocon Special Economic Zone, Biocon Park, Plot No. 2 and 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bengaluru 560 099, Karnataka, India.

Some of the Milestones:

• 1994: It initiated operations as a CRO with services in chemistry and biology.
• 1998: It granted 100% Export Oriented Unit (EOU) status by the Government of India.
• 1999: Its first operational expansion in R&D by way of expansion of lab space to over 23,000 sq. Ft.
• 2000: Also, CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
• 2001: It forayed into chemical development with a dedicated manufacturing facility.
• 2003: It moved to Biocon Park, a 90-acre biopharmaceutical SEZ with the operations spread over 65,000 sq. Ft.
• 2007:
• Both Bristol-Myers Squibb and the Company signed the first long term contract to set up the first dedicated R&D center.
• The expansion of research facilities located at Biocon SEZ to 148,000 sq. Ft.
• It crossed an annual turnover of over `1,000 million in Financial Year 2007.
• 2009:
• Both Dupont Crop Protection and the Company extended a partnership for R&D services.
• The expansion of manufacturing services with a new plant which is cGMP compliant.
• It initiated operations in safety assessment and large molecules development services.
• 2010:
• Also, the acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, FDA.
• It initiated operations in formulation development.
• 2011: Both Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer.
• 2012:
• Both Abbott and the Company collaborated to establish Abbott's nutrition research and development center in India and the second R&D center.
• It received the certification of the clinical facilities by ANVISA.
• It acquired a 100% stake in Clinigene International Limited from Biocon.
• 2013:
• It crossed an annual turnover of over INR 5,000 million in Financial Year 2013.
• Also, the Baxter International Inc. collaborated with the Company to establish the ‘Baxter Global Research Center,’ the third dedicated R&D center.
• The acceptance of the control testing laboratory by the Department of Health & Human Services, FDA.
• 2014:
• Both Bristol-Myers Squibb and the Company extend collaboration for its dedicated R&D center till 2020.
• The